151 Diagnostic utility of molecular and imaging biomarkers 2 Table 23. Estimated pooled test performance of combined BRAF/RAS mutation analysis in Bethesda III thyroid nodules ni Bethesda III test + (BRAF+) test + (RAS+) test - test ? nH (%) TP FP FN TN malignant (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) Nikiforov 2011 247 5 19 223 0 247 (100%) 21 3 14 209 14% 60 (42-76) 99 (96-100) 42.40 (13.35-134.67) 0.41 (0.27-0.61) BeaudenonHuibregtse 2014 42 0 7 35 0 22 (52%) 4 1 7 10 26% 36 (11-69) 91 (59-100) 4.00 (0.53-30.33) 0.70 (0.43-1.14) Danilovic 2014 116 15 0 101 0 116 (100%) 15 0 8 93 20% 65 (43-84) 100 (96-100) 121.42 (7.53-1,957.62) 0.36 (0.21-0.61) Hwang 2015 564 57 47 453 7 86 (15%) 70 1 13 2 15% 84 (75-91) 67 (9-99) 2.53 (0.51-12.57) 0.23 (0.09-0.60) Nikiforov 2015 462 2 17 443 0 95 (21%) 13 3 9 70 5% 59 (36-79) 96 (88-99) 14.38 (4.50-45.93) 0.43 (0.26-0.71) Rossi 2015 81 9 4 68 0 23 (28%) 9 3 1 10 12% 90 (55-100) 77 (46-95) 3.90 (1.42-10.75) 0.13 (0.02-0.85) Valderrabano 2016 47 0 0 46 1 19 (41%) 0 0 3 16 6% 0 (0-71) 100 (79-100) 4.25 (0.10-183.55) 0.90 (0.62-1.32) POOLED RESULTS 1,559 88 94 1,369 8 608 (39.2%) 132 11 55 410 12.0% 65.0 (48.4-78.6) 97.1 (88.5-99.3) 22.18 (6.37-77.27) 0.36 (0.24-0.55) FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. nH: number of indeterminate thyroid nodules with conclusive index test and histopathological follow-up. ni: number of indeterminate thyroid nodules. test+: number of positive index tests. test-: number of negative index tests. test?: number of unknown or nondiagnostic index tests. TN: true negative. TP: true positive.
RkJQdWJsaXNoZXIy MTk4NDMw